Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Pacific Biosciences Of California | 415.91 Mn | 139.95 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.50% |
| Dec 31, 2025 | -6.24% |
| Sep 30, 2025 | 9.37% |
| Jun 30, 2025 | 90.16% |
| Mar 31, 2025 | -18,070.27% |
| Dec 31, 2024 | 103.90% |
| Sep 30, 2024 | 64.96% |
| Jun 30, 2024 | -121.70% |
| Mar 31, 2024 | 4.68% |
| Dec 31, 2023 | -22.65% |
| Sep 30, 2023 | 4.24% |
| Jun 30, 2023 | 20.66% |
| Mar 31, 2023 | -4.30% |
| Dec 31, 2022 | -9.63% |
| Sep 30, 2022 | -7.81% |
| Jun 30, 2022 | 12.40% |
| Mar 31, 2022 | -17.55% |
| Jun 30, 2021 | -131.85% |
| Mar 31, 2021 | -150.76% |
| Dec 31, 2020 | 416.07% |